All In Biotech

Drug Trial Radar · NCT03783429

Digoxin Evaluation in Chronic Heart Failure: Investigational Study In Outpatients in the Netherlands

Last checked: Nov 19, 2026Latest source record: Apr 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 982 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

982

Actual

Start

Jul 1, 2020

Primary completion

Nov 13, 2025

Study completion Nov 13, 2025

Sponsor

Lead sponsor
University Medical Center GroningenAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Disphar International B.V.; Teva Nederland BV; Tiofarma BV; Netherlands Heart Foundation; Werkgroep Cardiologische centra Nederland
First posted
Dec 21, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Digoxin is the oldest, market-authorized drug for heart failure (HF), and very cheap. A large trial with digoxin, the DIG trial, executed in the early nineties revealed a highly significant reduction in HF hospitalizations, but no effect on mortality. A post-hoc analysis of the DIG trial suggests that low serum concentrations of digoxin may not only improve HF hospitalizations but also mortality in chronic HF patients. To confirm these retrospective analyses, a prospective, randomized, placebo-controlled trial is necessary to establish the position of digoxin in the contemporary treatment of HF. Therefore, the investigators examine whether low-level, aiming for serum concentrations 0.5-0.9ng/mL, digoxin is beneficial in HF patients with reduced or mid-range ejection fractions (LVEF \<50%).

Conditions

  • Heart Failure

Interventions

  • DigoxinDrug

    Digoxin tablets will be given orally

  • PlacebosDrug

    Placebo tablets will be given orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To demonstrate whether low-dose digoxin compared to placebo reduces the rate of the composite CV outcomeTime frame: Median of 3 years

Locations

44 sites in 1 country. Site status is shown where the registry gives one.

  • Noordwest Ziekenhuisgroep

    Alkmaar, Netherlands

  • Zorggroep Twente

    Almelo, Netherlands

  • Meander Medisch Centrum

    Amersfoort, Netherlands

  • BovenIJ Ziekenhuis

    Amsterdam, Netherlands

  • Gelre Ziekenhuizen

    Apeldoorn, Netherlands

  • Rijnstate Ziekenhuis

    Arnhem, Netherlands

  • Rode Kruis Ziekenhuis

    Beverwijk, Netherlands

  • Tergooi

    Blaricum, Netherlands

  • Amphia Ziekenhuis

    Breda, Netherlands

  • Ijsselland Ziekenhuis

    Capelle aan den IJssel, Netherlands

  • Reinier de Graaf Gasthuis

    Delft, Netherlands

  • Deventer Ziekenhuis

    Deventer, Netherlands

  • Van Weel Bethesda

    Dirksland, Netherlands

  • Slingeland Ziekenhuis

    Doetinchem, Netherlands

  • Ziekenhuis Gelderse Vallei

    Ede, Netherlands

  • Scheper Ziekenhuis

    Emmen, Netherlands

  • Admiraal de Ruyter Ziekenhuis

    Goes, Netherlands

  • Beatrix Ziekenhuis

    Gorinchem, Netherlands

  • Groene Hart Ziekenhuis

    Gouda, Netherlands

  • Martini Ziekenhuis

    Groningen, Netherlands

  • University Medical Center Groningen

    Groningen, Netherlands

  • Spaarne Gasthuis

    Haarlem, Netherlands

  • Saxenburgh MC

    Hardenberg, Netherlands

  • Ziekenhuis St Jansdal

    Harderwijk, Netherlands

  • Zuyderland Medisch Centrum

    Heerlen, Netherlands

  • Elkerliek Ziekenhuis

    Helmond, Netherlands

  • Bethesda

    Hoogeveen, Netherlands

  • Medisch Centrum Leeuwarden

    Leeuwarden, Netherlands

  • Alrijne Ziekenhuis

    Leiden, Netherlands

  • Maastricht UMC+

    Maastricht, Netherlands

  • Isala Diaconessenhuis

    Meppel, Netherlands

  • Radboud University Medical Center

    Nijmegen, Netherlands

  • Bravis ziekenhuis

    Roosendaal, Netherlands

  • Erasmus Medisch Centrum

    Rotterdam, Netherlands

  • Franciscus Gasthuis

    Rotterdam, Netherlands

  • Ikazia Ziekenhuis

    Rotterdam, Netherlands

  • Franciscus Vlietland

    Schiedam, Netherlands

  • Antonius Ziekenhuis Sneek

    Sneek, Netherlands

  • Refaja

    Stadskanaal, Netherlands

  • Haaglanden Medisch Centrum

    The Hague, Netherlands

Showing 40 of 44 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.